The TBPod

The TBPod is a podcast for clinicians and policymakers caring for patients with tuberculosis. The podcasts present discussions with expert clinicians, researchers, policymakers and advocates about their work in the field of tuberculosis. Tuberculosis remains one of the leading causes of death worldwide, and is an important contributor to morbidity among migrants arriving in Australia and New Zealand. There are around 1300 reported cases of TB in Australia each year, and a further 300 in New Zealand. Included in these figures are cases of multi-drug resistant (MDR) TB which pose significant barriers to treatment and management of the disease. The Australian government has committed to the global elimination of TB by 2030, but to do so requires the development of innovative new strategies, based on high-quality research, that has national and international reach. These podcasts aim to engage and update those who are interested in the field of tuberculosis through discussions with leaders in the field of tuberculosis.

All Episodes

The TBPod

Predicting Side Effects in 3HP

January 01, 2023 • Actnet

Today we speak with Professor Jann-Yuan Wang, a clinician and researcher in Taiwan, about his work in latent tuberculosis. Professor Wang speaks about his experience using 3HP and the challenges of systemic drug reactions. Professor Wang talks about his research into predicting which patients will experience systemic drug reactions based on research algorithms of clinical characteristics, plasma drug levels and transcriptomic factors.

REFERENCES:
1) Lee, Ming‐Chia, et al. "Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis." British journal of clinical pharmacology (2022).
2) Peng, Tzu-Rong, et al. "Advantages of short-course rifamycin-based regimens for latent tuberculosis infection: an updated network meta-analysis." Journal of Global Antimicrobial Resistance 29 (2022): 378-385.
3) Huang, Hung-Ling, et al. "Whole-blood 3-gene Signature as a Decision Aid for Rifapentine-based TB Preventive Therapy." Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America (2022).
4) Huang, Hung-Ling, et al. "Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection." Clinical Infectious Diseases 73.5 (2021): e1064-e1071.
5) Lee, Meng-Rui, et al. "Isoniazid concentration and NAT2 genotype predict risk of systemic drug reactions during 3HP for LTBI." Journal of clinical medicine 8.6 (2019): 812.
6) Sun, Hsin-Yun, et al. "Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan." Tuberculosis 111 (2018): 121-126.
7) Lee, Meng-Rui, et al. "Plasma Concentration of Isoniazid and Single-Nucleotide Polymorphisms of N-Acetyltransferase 2 Predict Risk of Systemic Drug Reactions During Weekly Rifapentine and Isoniazid Therapy for Latent Tuberculosis Infection: A Prospective Observational Cohort Study." Available at SSRN 3297903 (2018).